Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRPT vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRPT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–3 Matrix Metrics)

SRPT Overall Winner 6-Pillar Tally: SRPT 5 – 1 FDMT Matrix Metrics: SRPT 6 – 3 FDMT

As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRPT carries a Unified Composite Score of 37.8/100 (SELL) at $15.14 (10.8x Forward P/E, -0.4% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin).

  • Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. -222.7% operating margin) and revenue trajectory (-4.5% vs. +4505.6% YoY).
  • Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRPT vs FDMT
SRPT NASDAQ Head-to-Head Winner
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.14
-5.76% 1D
Market Cap $1.7B
TTM Revenue $1.96B
Forward P/E 10.8x
Beta / 30D Vol 1.47β · 58% Vol
Unified Composite Score
37.8 / 100 SELL
Tech 32.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.9%), weak momentum, RSI 33
RSI-14: 33.0 · SMA20: $17.82 · SMA50: $18.44
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (SRPT 5 – 1 FDMT)

Columns: Metric · SRPT · FDMT
1. Valuation Multiples SRPT
Forward P/E 10.8x N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.2x 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) -4.5% +4505.6%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $1.96B $96M
Market Cap $1.7B $669.3M
3. Profitability & Quality SRPT
Gross Margin 23.4% N/A
Operating Margin -0.4% -222.7%
Net Profit Margin -5.9% -208.6%
Return on Equity (ROE) -8.1% -56.7%
4. Balance Sheet & Cash Flow SRPT
Cash Generation (TTM) $172M -$156M
Cash Flow Margin 8.8% N/A
Net Cash / Leverage $580M Net Debt (0.69x D/E) $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRPT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 54.5% (7th %ile) 82.4% (10th %ile)
Put/Call OI Skew 0.66x (Call-Skewed) 5.16x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SRPT
OpEx & R&D Intensity 23.8% of Rev ($466M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRPT (6) vs FDMT (3)
Institutional Metric SRPT FDMT Criterion Row Edge
Market Capitalization
Scale
$1.7B $669.3M Larger Scale SRPT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
10.8x N/M Lower Multiple SRPT
Revenue Growth (YoY)
Growth
-4.5% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-0.4% -222.7% Higher Margin SRPT
Net Profit Margin
Profitability
-5.9% -208.6% Higher Margin SRPT
Return on Equity (ROE)
Capital Efficiency
-8.1% -56.7% Higher ROE SRPT
52-Week Range Position
Momentum
5% ($15–$25) 47% ($7–$17) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.47β · 58% Vol 1.89β · 90% Vol Lower Realized Risk SRPT
Unified Institutional Score
Composite Signal
37.8 / 100 (SELL) 51.3 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
$1.96B $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$172M ($580M Net Debt (0.69x D/E)) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +7.4 pp
SRPT: -11.44% · FDMT: -4.04%
3M Horizon SRPT +4.9 pp
SRPT: -15.96% · FDMT: -20.86%
6M Horizon FDMT +50.24 pp
SRPT: -10.97% · FDMT: +39.27%
1Y Horizon FDMT +28.35 pp
SRPT: -15.02% · FDMT: +13.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRPT Revenue FDMT Revenue SRPT Op. Margin FDMT Op. Margin Margin Leader
FY2018 $300M N/A -114.1% N/A SRPT
FY2019 $380M $10M -185.3% -729.4% SRPT
FY2020 $460M $10M -123.8% -424.0% SRPT
FY2021 $610M $20M -75.1% -395.5% SRPT
FY2022 $840M $0M -63.5% -3516.5% SRPT
FY2023 $1.14B $20M -23.4% -544.6% SRPT
FY2024 $1.79B $0M 12.2% -507678.4% SRPT
FY2025 $1.86B $90M -37.5% -187.2% SRPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRPT BREAKDOWN
52d in phase · OBV DISTRIBUTION
Current IV 54.5%
IV Percentile 7th %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SRPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -0.4% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($466M)
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRPT vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRPT carries a Unified Composite Score of 37.8/100 (SELL) at $15.14 (10.8x Forward P/E, -0.4% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. -222.7% operating margin) and revenue trajectory (-4.5% vs. +4505.6% YoY). Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: SRPT posts -4.5% YoY revenue growth and N/A YoY earnings growth on $1.96B TTM revenue (23.4% gross margin, -0.4% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SRPT cumulative revenue shifted +520.0% while FDMT shifted +800.0%. In operating R&D and SG&A reinvestment, SRPT deploys 23.8% of Rev ($466M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

SRPT screens cheaper on headline valuation multiples. SRPT trades at 10.8x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (8.8% FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRPT (-8.1% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SRPT carries 54.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 58% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.